These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

561 related items for PubMed ID: 20549962

  • 1. [Antifungal susceptibilities of Aspergillus spp. strains isolated from invasive aspergillosis cases].
    Gürcan S, Tikveşli M, Eryildiz C, Evci C, Ener B.
    Mikrobiyol Bul; 2010 Apr; 44(2):273-8. PubMed ID: 20549962
    [Abstract] [Full Text] [Related]

  • 2. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
    Direkel S, Otağ F, Aslan G, Ulger M, Emekdaş G.
    Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
    [Abstract] [Full Text] [Related]

  • 3. [Comparison of broth microdilution and E-test methods for the antifungal susceptibility testing of Candida spp. strains isolated from blood cultures].
    Ozcan SK, Mutlu B, Dündar D, Willke A.
    Mikrobiyol Bul; 2010 Apr; 44(2):263-71. PubMed ID: 20549961
    [Abstract] [Full Text] [Related]

  • 4. [Aspergillus spp. isolations from respiratory tract samples in Trakya University Hospital].
    Gürcan S, Demir M, Altiay G, Tikveşli M, Kiliç H, Otkun M.
    Tuberk Toraks; 2007 Apr; 55(2):160-6. PubMed ID: 17602344
    [Abstract] [Full Text] [Related]

  • 5. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
    Kaya AD, Kiraz N.
    Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
    [Abstract] [Full Text] [Related]

  • 6. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY, Xu YC, Shi Y, Lü HX, Liu Y, Zhao WS, Chen DM, Xi LY, Zhou X, Wang H, Guo LN.
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [Abstract] [Full Text] [Related]

  • 7. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
    Öz Y, Özdemir HG, Gökbolat E, Kiraz N, Ilkit M, Seyedmousavi S.
    Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
    [Abstract] [Full Text] [Related]

  • 8. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.
    Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
    [Abstract] [Full Text] [Related]

  • 9. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group.
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [Abstract] [Full Text] [Related]

  • 10. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
    Mallié M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, Chandenier J, Chauveau V, Couprie B, Datry A, Feuilhade M, Grillot R, Guiguen C, Lavarde V, Letscher V, Linas MD, Michel A, Morin O, Paugam A, Piens MA, Raberin H, Tissot E, Toubas D, Wade A.
    Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
    [Abstract] [Full Text] [Related]

  • 11. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S, Sancak B, Alp S, Hascelik G, McNicholas P.
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [Abstract] [Full Text] [Related]

  • 12. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
    Shivaprakash MR, Geertsen E, Chakrabarti A, Mouton JW, Meis JF.
    Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the activities of amphotericin B, itraconazole, and voriconazole against clinical and environmental isolates of Aspergillus species.
    Misra R, Malik A, Singhal S.
    Indian J Pathol Microbiol; 2011 Sep; 54(1):112-6. PubMed ID: 21393890
    [Abstract] [Full Text] [Related]

  • 14. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
    Paterson PJ, Seaton S, Prentice HG, Kibbler CC.
    J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy.
    Amorim A, Guedes-Vaz L, Araujo R.
    Int J Antimicrob Agents; 2010 Apr; 35(4):396-9. PubMed ID: 20138740
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.